NICE Likely To Lose Cost-Watchdog Status By 2013
This article was originally published in The Pink Sheet Daily
Executive Summary
A new value-based pricing system will make NICE's cost-assessment role redundant, say U.K. ministers.
You may also be interested in...
NICE Will Have Key Role in Value-Based Pricing Under U.K. Health Care Reforms
NICE to be placed on a firmer statutory footing and given a new name, as well as a role in determining the value of medicines.
NICE Will Have Key Role in Value-Based Pricing Under U.K. Health Care Reforms
NICE to be placed on a firmer statutory footing and given a new name, as well as a role in determining the value of medicines.
Avastin's Stumble Again At NICE Underscores Importance Of Overall Survival Data
NICE rejection of Roche's Avastin comes a week ahead of target dates for U.S. and EU decisions on possibly withdrawing the indication, but still offers instructive lessons for working with technology assessment groups.